Skip to content

PILOT Quality check of PSMA PET for imaging salivary gland toxicity

PILOT Quality check of PSMA PET for imaging salivary gland toxicity - PILOT Quality PSMA PET for salivary gland toxicity

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42838
Enrollment
5
Registered
2016-08-12
Start date
2016-08-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxiciteit in speekselklieren van uitwendige bestraling Salivary gland toxicity Xerostomia

Interventions

Salivary glands
Toxicity

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients with HNSCC, who were treated 6-12 months ago with (CC)RT of one neck side with curative intent, and who received variable doses to the major salivary glands at the irradiated side with at least one gland receiving a significant part >36Gy EQD2.

Exclusion criteria

Exclusion criteria: Pregnancy, lactation, inability to provide informed consent

Design outcomes

Primary

MeasureTime frame
The image quality will be evaluated visually with respect to spatial resolution, signal-to-noise levels and artefacts. The signal reduction due to external beam irradiation will be interpreted visually, while considering relatively spared regions and known normal uptake patterns in healthy gland tissues. An expert panel will review if the PSMA PET/CT scans are adequate (feasible) for the application in the anticipated study protocol.

Secondary

MeasureTime frame
Not applicable.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)